Total Payments
$382,751
2024 Payments
$23,525
Companies
63
Transactions
1,249
Medicare Patients
5,029
Medicare Billing
$447,041
Payment Breakdown by Category
Other$323,530 (84.5%)
Travel$25,632 (6.7%)
Food & Beverage$23,603 (6.2%)
Consulting$9,456 (2.5%)
Education$530.89 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $323,530 | 150 | 84.5% |
| Travel and Lodging | $25,632 | 139 | 6.7% |
| Food and Beverage | $23,603 | 923 | 6.2% |
| Consulting Fee | $9,456 | 13 | 2.5% |
| Education | $530.89 | 24 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $152,095 | 241 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $93,093 | 195 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $35,282 | 111 | $0 (2019) |
| Regeneron Healthcare Solutions, Inc. | $25,104 | 66 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $19,188 | 80 | $0 (2024) |
| Mylan Specialty L.P. | $17,123 | 54 | $0 (2024) |
| IDORSIA PHARMACEUTICALS US INC | $16,249 | 25 | $0 (2024) |
| Harmony Biosciences LLC | $10,561 | 42 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $2,115 | 23 | $0 (2022) |
| Actelion Pharmaceuticals US, Inc. | $1,983 | 92 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,525 | 42 | AstraZeneca Pharmaceuticals LP ($6,611) |
| 2023 | $77,832 | 183 | GlaxoSmithKline, LLC. ($26,202) |
| 2022 | $61,442 | 175 | GlaxoSmithKline, LLC. ($28,881) |
| 2021 | $54,289 | 130 | GlaxoSmithKline, LLC. ($24,024) |
| 2020 | $43,498 | 122 | GlaxoSmithKline, LLC. ($27,481) |
| 2019 | $58,972 | 230 | GlaxoSmithKline, LLC. ($39,050) |
| 2018 | $19,045 | 180 | AstraZeneca Pharmaceuticals LP ($8,170) |
| 2017 | $44,147 | 187 | AstraZeneca Pharmaceuticals LP ($24,573) |
All Payment Transactions
1,249 individual payment records from CMS Open Payments — Page 1 of 50
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $701.25 | General |
| Category: Respiratory | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $665.89 | General |
| Category: Respiratory | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Travel and Lodging | In-kind items and services | $296.62 | General |
| Category: Respiratory | ||||||
| 10/19/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | In-kind items and services | $40.26 | General |
| Category: Respiratory | ||||||
| 10/08/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $81.77 | General |
| Category: Immunology | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $450.00 | General |
| Category: Respiratory | ||||||
| 08/29/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 08/22/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $13.14 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Respiratory | ||||||
| 08/02/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,625.00 | General |
| Category: IMMUNOLOGY | ||||||
| 07/19/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $619.00 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 07/04/2024 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $150.00 | General |
| Category: Respiratory | ||||||
| 05/13/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $14.69 | General |
| Category: NEUROSCIENCE | ||||||
| 04/18/2024 | ABBVIE INC. | UBRELVY (Drug), SYNTHROID | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: NEUROSCIENCE | ||||||
| 03/05/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $1.61 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 03/02/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Travel and Lodging | In-kind items and services | $119.97 | General |
| Category: NEUROLOGY | ||||||
| 02/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,900.00 | General |
| Category: IMMUNOLOGY | ||||||
| 02/28/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,870.00 | General |
| Category: NEUROLOGY | ||||||
| 02/28/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Travel and Lodging | Cash or cash equivalent | $39.18 | General |
| Category: IMMUNOLOGY | ||||||
| 02/26/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,957.50 | General |
| Category: Insomnia | ||||||
| 02/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: RESPIRATORY | ||||||
| 02/23/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $6.73 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 02/21/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $69.84 | General |
| Category: Insomnia | ||||||
| 02/19/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $12.82 | General |
| Category: VACCINES | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 18 | 1,450 | 2,466 | $242,687 | $112,759 |
| 2022 | 17 | 1,126 | 1,770 | $206,720 | $99,287 |
| 2021 | 20 | 1,132 | 1,571 | $240,540 | $112,896 |
| 2020 | 23 | 1,321 | 1,783 | $279,603 | $122,100 |
Total Patients
5,029
Total Services
7,590
Medicare Billing
$447,041
Procedure Codes
78
All Medicare Procedures & Services
78 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 321 | 743 | $124,824 | $64,214 | 51.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 89 | 91 | $20,930 | $11,291 | 53.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 169 | 175 | $14,875 | $6,970 | 46.9% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 169 | 175 | $13,125 | $6,687 | 50.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 51 | 51 | $11,220 | $5,792 | 51.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 172 | 178 | $11,926 | $4,805 | 40.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 45 | 51 | $6,120 | $3,048 | 49.8% |
| 95810 | Sleep study in sleep lab (6 years or older) | Office | 2023 | 30 | 30 | $7,620 | $2,595 | 34.1% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2023 | 23 | 25 | $8,925 | $2,287 | 25.6% |
| 31622 | Diagnostic exam of lung airway using an endoscope | Facility | 2023 | 17 | 17 | $7,650 | $1,664 | 21.8% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 156 | 161 | $3,381 | $1,001 | 29.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 51 | 83 | $2,656 | $839.01 | 31.6% |
| 95806 | Sleep study including heart rate, breathing, airflow, and effort | Office | 2023 | 14 | 15 | $5,220 | $504.30 | 9.7% |
| 71046 | X-ray of chest, 2 views | Office | 2023 | 26 | 26 | $1,118 | $405.60 | 36.3% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 39 | 40 | $680.00 | $336.00 | 49.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 12 | 12 | $240.00 | $235.20 | 98.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 44 | 494 | $494.00 | $45.70 | 9.3% |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | Office | 2023 | 22 | 99 | $1,683 | $38.88 | 2.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 305 | 670 | $112,560 | $60,620 | 53.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 73 | 73 | $16,790 | $9,592 | 57.1% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 109 | 109 | $9,145 | $4,614 | 50.5% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 109 | 109 | $7,995 | $4,332 | 54.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 128 | 130 | $8,710 | $3,718 | 42.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 31 | 31 | $6,568 | $3,452 | 52.6% |
| 95811 | Sleep study in sleep lab with continuous airway pressure (6 years or older) | Office | 2022 | 32 | 34 | $12,138 | $3,277 | 27.0% |
About Dr. Jonathan Evans, M.D
Dr. Jonathan Evans, M.D is a Pulmonary Disease healthcare provider based in South Portland, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/12/2005. The National Provider Identifier (NPI) number assigned to this provider is 1568460640.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Evans, M.D has received a total of $382,751 in payments from pharmaceutical and medical device companies, with $23,525 received in 2024. These payments were reported across 1,249 transactions from 63 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($323,530).
As a Medicare-enrolled provider, Evans has provided services to 5,029 Medicare beneficiaries, totaling 7,590 services with total Medicare billing of $447,041. Data is available for 4 years (2020–2023), covering 78 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Other Specialties Sleep Medicine, Pulmonary Disease
- Location South Portland, ME
- Active Since 07/12/2005
- Last Updated 02/12/2024
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1568460640
Products in Payments
- TRELEGY ELLIPTA (Drug) $75,451
- BREZTRI (Drug) $50,519
- NUCALA (Biological) $45,699
- DUPIXENT (Biological) $25,340
- BEVESPI AEROSPHERE (Drug) $25,007
- XYWAV (Drug) $18,272
- UTIBRON (Drug) $17,843
- LONHALA MAGNAIR (Drug) $17,351
- QUVIVIQ (Drug) $16,249
- Yupelri (Drug) $14,113
- Wakix (Drug) $10,561
- ANORO (Drug) $7,691
- BREZTRI AEROSPHERE (Drug) $7,152
- SYMBICORT (Drug) $6,757
- YUPELRI (Drug) $2,913
- DALIRESP (Drug) $2,434
- XOLAIR (Biological) $1,987
- UPTRAVI (Drug) $1,592
- GENERAL PULMONARY (Device) $807.80
- OFEV (Drug) $744.54
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in South Portland
Dr. Richard Riker, M.d, M.D
Pulmonary Disease — Payments: $27,426
Pulmonary Disease $27,426
Dr. Joel Wirth, M.d, M.D
Pulmonary Disease — Payments: $10,415
Pulmonary Disease $10,415
Dr. Jonathan Zuckerman, Md, MD
Pulmonary Disease — Payments: $4,489
Pulmonary Disease $4,489
Dr. Jason Yahwak, M.d, M.D
Pulmonary Disease — Payments: $1,208
Pulmonary Disease $1,208
Dr. Stephen Gorman, D.o, D.O
Pulmonary Disease — Payments: $33.73
Pulmonary Disease $33.73
Dr. Thomas Van Der Kloot, M.d, M.D
Pulmonary Disease — Payments: $12.59
Pulmonary Disease $12.59